+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 79Years
All Genders
Healthy Volunteers
ID07287137

Comparison of Immune Responses to Novavax and Pfizer-BioNTech COVID-19 Vaccines in Adults with Risk Factors for Severe COVID-19

Led by Henry M. Jackson Foundation for the Advancement of Military Medicine · Updated on 2026-11-02

54

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the immune responses and side effects of FDA-approved vaccines for COVID-19 and influenza in the Comparative Immunogenicity of Respiratory Virus Vaccines CIRV2 study. This Phase IV trial focuses on adults aged 18 to 79 who have certain risk factors for severe COVID-19 but do not have severe immune system impairments. In 2026, the study compares two COVID-19 vaccines the Novavax recombinant vaccine and the Pfizer-BioNTech mRNA vaccine. Participants will be randomly assigned to receive either the Pfizer-BioNTech mRNA COVID-19 vaccine or the Novavax recombinant protein vaccine. The study involves vaccination followed by blood sample collections to measure immune responses before vaccination, 30 days after, and 150 days after vaccination in the second year, with the first year including assessments before vaccination and 30 days after. This allows researchers to track the bodys antibody levels and neutralizing antibody activity over time. During the study, participants will attend clinic visits around 30 days and 150 days post-vaccination and complete online follow-ups for up to 9 months. Blood samples will be analyzed to assess IgG binding antibody levels and neutralizing antibody titers. The study team monitors participants for vaccine reactions and immune responses to better understand differences between the vaccines. Total participation lasts around one year, with ongoing assessments to evaluate vaccine effectiveness and safety.

CONDITIONS

Brief Title

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Research Team

M

Marianne Spevak, BSHS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here